Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2010 May 11

PMID 20451522

Citations 281

Authors

Jody Dushay

Patricia C Chui

Gosala S Gopalakrishnan

Marta Varela-Rey

Meghan Crawley

Ffolliott M Fisher

Michael K Badman

Maria L Martinez-Chantar

Eleftheria Maratos-Flier

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Fibroblast growth factor 21 (FGF21) is an hepatic protein that plays a critical role in metabolism, stimulating fatty acid oxidation in liver and glucose uptake in fat. Systemic administration to obese rodents and diabetic monkeys leads to improved glucose homeostasis and weight loss. In rodents, FGF21 increases with fasting and consumption of a ketogenic diet (KD). In humans, FGF21 correlates with body mass index (BMI), but studies evaluating other parameters show inconsistent results. We examined FGF21 serum levels in lean and obese individuals and in response to dietary manipulation. We also evaluated FGF21 serum levels and liver messenger RNA (mRNA) expression in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Methods: Serum FGF21 was measured after an overnight fast in individuals with BMI ranging from normal to obese. Volunteers fasted for 16 or 72 hours and then ate a standard meal. Another group consumed KD for 12 days. Serum FGF21 and hepatic mRNA expression were measured in obese individuals with NAFLD or NASH.

Results: There was a positive correlation between BMI and FGF21. There was no change in FGF21 in response to a short fast or KD. A nonstatistically significant fall in FGF21 levels was seen after a 72-hour fast. Hepatic FGF21 mRNA expression was significantly elevated in NAFLD, which correlated with a substantial increase in serum FGF21. In NASH, serum FGF21 but not liver mRNA was increased.

Conclusions: FGF21 correlates with BMI and may be a novel biomarker for NAFLD, but is not nutritionally regulated in humans.

Citing Articles

The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice.

Di Vincenzo A, Granzotto M, Crescenzi M, Fioretto P, Vettor R, Rossato M BMC Endocr Disord. 2025; 25(1):63.

PMID: 40059147 PMC: 11892253. DOI: 10.1186/s12902-025-01879-3.

Assessment of skeletal muscle alterations and circulating myokines in metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.

Real Martinez Y, Fernandez-Garcia C, Fuertes-Yebra E, Calvo Soto M, Berlana A, Barrios V World J Gastroenterol. 2025; 31(7):100039.

PMID: 39991673 PMC: 11755261. DOI: 10.3748/wjg.v31.i7.100039.

The Impact of Human Liver Transplantation on the Concentration of Fibroblast Growth Factors: FGF19 and FGF21.

Budkowska M, Ostrycharz-Jasek E, Cecerska-Heryc E, Dolegowska K, Siennicka A, Nazarewski L Int J Mol Sci. 2025; 26(3).

PMID: 39941067 PMC: 11818808. DOI: 10.3390/ijms26031299.

Metabolic and Hepatic Profiles of Non-Obese and Obese Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents: The Role of FibroScan Parameters,Fibroblast Growth Factor-21, and Cytokeratin-18.

Keskin M, Arsoy H, Kara O, Sarandol E, Beyaz A, Koca N Turk J Gastroenterol. 2025; .

PMID: 39910885 PMC: 11900013. DOI: 10.5152/tjg.2025.24760.

Potential therapeutic strategies for MASH: from preclinical to clinical development.

Xie Z, Li Y, Cheng L, Huang Y, Rao W, Shi H Life Metab. 2025; 3(5):loae029.

PMID: 39872142 PMC: 11749562. DOI: 10.1093/lifemeta/loae029.

References

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

Berglund E, Li C, Bina H, Lynes S, Michael M, Shanafelt A . Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology. 2009; 150(9):4084-93. PMC: 2736088. DOI: 10.1210/en.2009-0221. View

Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V . Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007; 5(6):415-25. DOI: 10.1016/j.cmet.2007.05.003. View

Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D . Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009; 71(3):369-75. DOI: 10.1111/j.1365-2265.2008.03502.x. View

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

Xu J, Stanislaus S, Chinookoswong N, Lau Y, Hager T, Patel J . Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab. 2009; 297(5):E1105-14. DOI: 10.1152/ajpendo.00348.2009. View

Li H, Bao Y, Xu A, Pan X, Lu J, Wu H . Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009; 94(6):2151-6. DOI: 10.1210/jc.2008-2331. View

Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F . Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009; 94(9):3594-601. DOI: 10.1210/jc.2009-0111. View

Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H . Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab. 2008; 93(9):3627-32. DOI: 10.1210/jc.2008-0746. View

10.

Lundasen T, Hunt M, Nilsson L, Sanyal S, Angelin B, Alexson S . PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 2007; 360(2):437-40. DOI: 10.1016/j.bbrc.2007.06.068. View

11.

Chavez A, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo R, Tripathy D . Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009; 32(8):1542-6. PMC: 2713625. DOI: 10.2337/dc09-0684. View

12.

Nishimura T, Nakatake Y, Konishi M, Itoh N . Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta. 2000; 1492(1):203-6. DOI: 10.1016/s0167-4781(00)00067-1. View

13.

Chen W, Li L, Yang G, Li K, Qi X, Zhu W . Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007; 116(1):65-8. DOI: 10.1055/s-2007-985148. View

14.

Li L, Yang G, Ning H, Yang M, Liu H, Chen W . Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract. 2008; 82(2):209-13. DOI: 10.1016/j.diabres.2008.07.012. View

15.

Tran T, Changsri C, Shackleton C, Poordad F, Nissen N, Colquhoun S . Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006; 21(2):381-3. DOI: 10.1111/j.1440-1746.2005.03968.x. View

16.

Kharitonenkov A, Wroblewski V, Koester A, Chen Y, Clutinger C, Tigno X . The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 2006; 148(2):774-81. DOI: 10.1210/en.2006-1168. View

17.

Kennedy A, Pissios P, Otu H, Roberson R, Xue B, Asakura K . A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab. 2007; 292(6):E1724-39. DOI: 10.1152/ajpendo.00717.2006. View

18.

Coskun T, Bina H, Schneider M, Dunbar J, Hu C, Chen Y . Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149(12):6018-27. DOI: 10.1210/en.2008-0816. View

19.

Galman C, Lundasen T, Kharitonenkov A, Bina H, Eriksson M, Hafstrom I . The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab. 2008; 8(2):169-74. DOI: 10.1016/j.cmet.2008.06.014. View

20.

Neuschwander-Tetri B, Caldwell S . Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37(5):1202-19. DOI: 10.1053/jhep.2003.50193. View